Medincell (XPAR:MEDCL) Dividend Payout Ratio : 0.00 (As of Sep. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Medincell Dividend Payout Ratio?

Medincell's dividend payout ratio for the months ended in Sep. 2023 was 0.00.

The historical rank and industry rank for Medincell's Dividend Payout Ratio or its related term are showing as below:

XPAR:MEDCL's Dividend Payout Ratio is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.44
* Ranked among companies with meaningful Dividend Payout Ratio only.

As of today (2024-06-05), the Dividend Yield % of Medincell is 0.00%.

Medincell's Dividends per Share for the months ended in Sep. 2023 was €0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Medincell Dividend Payout Ratio Historical Data

The historical data trend for Medincell's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medincell Dividend Payout Ratio Chart

Medincell Annual Data

Trend

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Dividend Payout Ratio

Get a 7-Day Free Trial

Medincell Semi-Annual Data
	Mar16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Dividend Payout Ratio	Get a 7-Day Free Trial										-	-	-	-	-

Competitive Comparison of Medincell's Dividend Payout Ratio

For the Biotechnology subindustry, Medincell's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Medincell's Dividend Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medincell's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where Medincell's Dividend Payout Ratio falls into.

Medincell Dividend Payout Ratio Calculation

Dividend payout ratio measures the percentage of the company's earnings paid out as dividends.

Medincell's Dividend Payout Ratio for the fiscal year that ended in Mar. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (A: Mar. 2023 )	/	EPS without NRI (A: Mar. 2023 )
	=	0	/	-1.269
	=	N/A

Medincell's Dividend Payout Ratio for the quarter that ended in Sep. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Sep. 2023 )	/	EPS without NRI (Q: Sep. 2023 )
	=	0	/	-0.29
	=	N/A

Medincell (XPAR:MEDCL) Dividend Payout Ratio Explanation

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

Medincell Dividend Payout Ratio Related Terms

Thank you for viewing the detailed overview of Medincell's Dividend Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Medincell (XPAR:MEDCL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medincell SA (XPAR:MEDCL) » Definitions » Dividend Payout Ratio

Comparable Companies

Traded in Other Exchanges

MEB:Germany

Address

3 rue des Freres Lumiere, Jacou, FRA, 34830

Website

https://www.medincell.com

Medincell SA is a technology-based pharmaceutical firm, aims to optimise the efficiency of medical treatments and make them accessible geographically. The company's product portfolio uses BEPO-patented technology to develop controlled, long-acting injectable medical treatments for a number of therapeutic fields. The firm has a single operating segment: ongoing research and development on processes that use biodegradable polymers to enable the controlled and prolonged release of the active principles of drugs into the human body and animals by means of injection.

Medincell (XPAR:MEDCL) Headlines

No Headlines